MRTX - ミラティ・セラピュ―ティックス (Mirati Therapeutics Inc.) ミラティ・セラピュ―ティックス

 MRTXのチャート


 MRTXの企業情報

symbol MRTx
会社名 Mirati Therapeutics Inc (ミラティ・セラピュ―ティックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Mirati Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company's clinical pipeline consists of three product candidates: MGCD265 MGCD516 and mocetinostat. MGCD265 and MGCD516 are orally-bioavailable spectrum-selective kinase inhibitors. Both MGCD265 and MGCD516 are in development to treat patients with non-small cell lung cancer (NSCLC) and other solid tumors. MGCD265 is in Phase Ib clinical development and MGCD516 is in the dose escalation phase of Phase I clinical development. Mocetinostat is an orally-bioavailable spectrum-selective histone deacetylase (HDAC) inhibitor which is in Phase II development. Mocetinostat is being developed for the second line treatment of patients with bladder cancer and non-hodgkins lymphoma (NHL) specifically focusing on diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).   ミラティ・セラピュ―ティックスは、臨床期の米国バイオ医薬品企業。一部の癌患者の治療のため医薬品開発に焦点を当てる。主な製品は、「MGCD265」、「MGCD516」と「mocetinostat」。非小細胞肺癌、頭頸部の扁平上皮癌、および他の固形腫瘍、骨髄異形成症候群を有する患者を治療するために製品を開発する。   
本社所在地 9393 Towne Centre Drive Suite 200 San Diego CA 92121 USA
代表者氏名 Rodney W. Lappe ロドニー・W・ラッペ
代表者役職名 Executive Independent Chairman of the Board
電話番号 +1 858-332-3410
設立年月日 41365
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 51人
url www.mirati.com
nasdaq_url https://www.nasdaq.com/symbol/mrtx
adr_tso
EBITDA EBITDA(百万ドル) -78.67100
終値(lastsale) 44.38
時価総額(marketcap) 1436071738.92
時価総額 時価総額(百万ドル) 1294.665
売上高 売上高(百万ドル) 9.46700
企業価値(EV) 企業価値(EV)(百万ドル) 134.481
当期純利益 当期純利益(百万ドル) -76.82300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Mirati Therapeutics Inc revenues increased from $0K to $9.5M. Net loss increased 18% to $42.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and develpment balancng value increase of 55% to $34.9M (expense) Stock-based Compensation in SGA increase from $2.1M to $4.3M (expense).

 MRTXのテクニカル分析


 MRTXのニュース

   Mirati Therapeutics to Present Late-Breaking Data That Advance the Understanding of Synthetic Lethal PRMT5 Inhibitors in MTAP-Deleted Cancers at AACR 2021  2021/03/10 21:39:00 PR Newswire
SAN DIEGO, March 10, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced it will present initial preclinical data on the Company's synthetic lethal PRMT5 inhibitor during a late-breaking minisymposium at the American…
   Oppenheimer Stick to Their Buy Rating for Mirati Therapeutics By Investing.com  2021/03/01 00:45:01 Investing.com
Oppenheimer Stick to Their Buy Rating for Mirati Therapeutics
   Mirati Therapeutics (NASDAQ:MRTX) Announces Quarterly Earnings Results  2021/02/26 21:32:53 Transcript Daily
Mirati Therapeutics (NASDAQ:MRTX) announced its quarterly earnings data on Thursday. The biotechnology company reported ($2.08) EPS for the quarter, topping the Zacks’ consensus estimate of ($2.23) by $0.15, MarketWatch Earnings reports. Mirati Therapeutics stock traded up $5.24 during mid-day trading on Friday, hitting $200.84. 23,535 shares of the company’s stock traded hands, compared to its […]
   Mirati Therapeutics Reports Fourth Quarter And Full-Year 2020 Financial Results And Recent Corporate Updates  2021/02/25 21:15:00 PR Newswire
SAN DIEGO, Feb. 25, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today reported financial results for the fourth quarter and full year of 2020, which reflect the company's progress across its clinical and discovery pipeline and…
   Global Advanced Urotheilal carcinoma Pipeline Insight Report 2021 Featuring Rogaratininb (Bayer) & Sitravatinib (Mirati Therapeutics) - ResearchAndMarkets.com  2021/02/23 12:36:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Advanced Urotheilal carcinoma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering. This "Advanced Urothelial Carcinoma - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Advanced Urothelial Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and non clinical stage products. It also covers the therapeutics assessment by product typ
   Mirati Therapeutics To Participate In The 2020 Evercore ISI HealthCONx Conference  2020/11/23 21:30:00 PR Newswire
SAN DIEGO, Nov. 23, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the 2020 Evercore ISI HealthCONx Conference on Tuesday, December 1st at 8:20 a.m. PT/11:20 a.m. ET….
   Mirati Therapeutics To Participate In The 29th Annual Credit Suisse Virtual Healthcare Conference  2020/11/05 21:30:00 PR Newswire
SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference on Thursday, November 12, 2020 at 9:30 a.m….
   The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping  2020/11/05 12:54:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 4) Abbott Laboratories (NYSE: ABT ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Ascendis Pharma A/S (NASDAQ: ASND ) Athira Pharma Inc (NASDAQ: ATHA ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BioLife Solutions Inc (NASDAQ: BLFS ) Cardiff Oncology Inc (NASDAQ: CRDF ) Denali Therapeutics Inc (NASDAQ: DNLI ) - moved in sympathy with Biogen Inc (NASDAQ: BIIB ) Guardant Health Inc (NASDAQ: GH ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Inspire Medical Systems Inc (NYSE: INSP ) Immunovant Inc (NASDAQ: IMVT ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kodiak Sciences Inc (NASDAQ: KOD ) Laboratory Corp.
   Oppenheimer Stick to Their Buy Rating for Mirati Therapeutics  2020/11/05 05:15:08 Investing.com
Oppenheimer Stick to Their Buy Rating for Mirati Therapeutics
   Mirati Therapeutics Reports Third Quarter 2020 Financial Results And Recent Business Highlights  2020/11/04 21:15:00 PR Newswire
SAN DIEGO, Nov. 4, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2020 and recent business highlights. "The third quarter was notable for significant…
   Mirati Therapeutics To Participate In The 29th Annual Credit Suisse Virtual Healthcare Conference  2020/11/05 21:30:00 PR Newswire
SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference on Thursday, November 12, 2020 at 9:30 a.m….
   The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping  2020/11/05 12:54:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 4) Abbott Laboratories (NYSE: ABT ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Ascendis Pharma A/S (NASDAQ: ASND ) Athira Pharma Inc (NASDAQ: ATHA ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BioLife Solutions Inc (NASDAQ: BLFS ) Cardiff Oncology Inc (NASDAQ: CRDF ) Denali Therapeutics Inc (NASDAQ: DNLI ) - moved in sympathy with Biogen Inc (NASDAQ: BIIB ) Guardant Health Inc (NASDAQ: GH ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Inspire Medical Systems Inc (NYSE: INSP ) Immunovant Inc (NASDAQ: IMVT ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kodiak Sciences Inc (NASDAQ: KOD ) Laboratory Corp.
   Oppenheimer Stick to Their Buy Rating for Mirati Therapeutics  2020/11/05 05:15:08 Investing.com
Oppenheimer Stick to Their Buy Rating for Mirati Therapeutics
   Mirati Therapeutics Reports Third Quarter 2020 Financial Results And Recent Business Highlights  2020/11/04 21:15:00 PR Newswire
SAN DIEGO, Nov. 4, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2020 and recent business highlights. "The third quarter was notable for significant…
   Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares  2020/10/30 21:09:00 PR Newswire
/PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 4,985,706…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ミラティ・セラピュ―ティックス MRTX Mirati Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)